Skip to main content

MicroRNAs involve in bicuspid aortic aneurysm: pathogenesis and biomarkers


The incidence of bicuspid aortic valves (BAV) is high in the whole population, BAV-related thoracic aortic aneurysm (TAA) is accompanied by many adverse vascular events. So far, there are two key points in dealing with BAV-related TAA. First is fully understanding on its pathogenesis. Second is optimizing surgical intervention time. This review aims to illustrate the potential role of miRNAs in both aspects, that is, how miRNAs are involved in the occurrence and progression of BAV-related TAA, and the feasibilities of miRNAs as biomarkers.

Peer Review reports


  1. 1.

    MiRNA involved in highly heterogeneous etiology of BAV-related TAA.

  2. 2.

    In BAV-related TAA, miRNA mainly targets ECM, VSMC and ECs.

  3. 3.

    MiRNA can be used as a biomarker to guide the timing of TAA surgery.


Bicuspid aortic valve (BAV) is one of the most prevalent congenital heart malformation with overall incidence of 1% to 2% [1]. This malformation is closely associated with a high risk of aortic valve dysfunction and thoracic aortic complications. In patients with BAV, the progressive dilation of thoracic aorta will be a critical focus complication. Without effective surgical intervention, progressive aortic dilation can result in aortic dissection (mortality of which averages 25% in its acute Stanford A-type) [2] and aortic rupture (mortality of which averages 57% in emergency operations) [3]. To avoid such catastrophic vascular events, essential treatments to progressive aortic dilation is aorta and/or aortic valves replacement.

Although surgical method improved greatly the prognosis of thoracic aortic aneurysm (TAA), uncertainties still remained in decision of time to start surgical intervention, partly because the imaging diagnosis and morphological presentation of TAA are not sufficient to give strong evidences for the timing of surgeries. According to a large clinical study in 2007, 59% of Type A aortic dissections occurred in patients with an aortic diameter of less than 5.5 cm, and 40% occurred in patients with an aortic diameter of less than 5.0 cm [4]. Furthermore, the adjacent distal aorta still has a potential risk of dilation after a successful aortic replacement surgery [5], resulting in reoperations that poses extra risk on the patients.

Recent studies reveal complexing and unique pathogenesis about BAV-related TAA including gene mutations [6], hemodynamics, mechanical stress [7], oxidation and inflammation, and their interactions. As a research hotspot up-to-date, miRNA has attracted much attention in regulating gene expression through translation repression and messenger RNA (mRNA) decay, which enables the abnormal expression of miRNA to participate in the occurrence and progression of various human diseases [8]. Especially, miRNA can be an important regulatory molecule in the studies of some diseases with high heterogeneity and unclear pathogenesis.

In this review, we try to summarize functions of miRNA and relationships between miRNA and BAV-related TAA; and to discuss potential applications of miRNA in diagnosis and treatment for BAV-related TAA.

Biological function of miRNA

miRNAs are a series of endogenous expression non-coding RNAs (ncRNA) that have a sequence-specific model guiding to the targets. They are classified into different families according to their seed sequences which are the main fragments binding to target genes [9]. Pre-miRNA is a semi-mature molecule with double strands to be separated. One strand is degraded to maintain the homeostasis of functional miRNA, the other strand functions actively to bind to specific regulating targets, including protein-coding mRNA and ncRNA [10].

miRNA cooperates with Argonaute (AGO) proteins to work as a functional complex [11]. AGO2 is ubiquitously intracellular expressed and participate in various of functions [12]. Domains in AGO are involved in the process of miRNA seed sequences recognizing target sites, and this process of recognition and binding is not highly conserved. In addition to strongest complementarity, there are other complementary ways with weak seed-match degrees [8]. The binding targets locate mainly within the 3’ untranslated regions (UTR) of mRNA, inducing translation inhibition and promotion of mRNA decay as main effects. Translation inhibition is achieved by assembling initiation factors and mRNA [13], and mRNA decay (major effects of miRNA) is conducted by enzymatic degradation followed by deadenylation of mRNA [14].

As a member of RNA, miRNA can be regulated by transcriptional promoting or inhibiting. What' more, degradation rates and epigenetic repression can also influence miRNAs' content. Post-transcriptional modifications of miRNA, such as uridylation, adenylated and oxidation [15,16,17], can change the stability and functions of miRNA.

The functions and characteristics of miRNA described above support the involvement of miRNA in the highly heterogeneous pathogenesis of BAV-related TAA.

In addition, most miRNAs have an average half-life of 119 h or slightly longer, but some also have a rapid change in their content [18]; moreover, miRNA remains highly stable in formalin-fixed tissues [19], and this characteristic can also be found in the serum. These specificities of miRNA support it as an effective and reliable biomarker.

Pathogenesis and phenotypic heterogeneity of BAV-related TAA

The pathogenic mechanism of BAV-related TAA

The pathogenesis of BAV has not been fully understood. Aortic root aneurysm and ascending aortic aneurysm are seen early in children with BAV, suggesting that genetic factors may be involved in the progression of the BAV-related TAA [20]. Family studies in monozygotic twins and first-degree relatives had revealed correlations between BAV and heredity [21, 22]. Some researchers have identified several risk factors for BAV-related TAA. In some research, mutation of the NOTCH1 gene is most closely related to the pathogenesis of BAV [23], but the positive detection rate of this mutation in isolated cases is not very high [24]. Other gene mutations, such as ROBO4 and MYH6 were also found in BAV patients [25, 26], some even contributed to syndromic phenotypes as well. Genetic factors of BAV-related TAA seem to be diverse, and are probably not quite deterministic or uniquely deterministic.

The influence of hemodynamic factors on the progression of BAV-related TAA has been widely demonstrated in recent years [7, 27]. Abnormal aortic valves structures produce faster blood spurts, resulting in a higher shear stress toward thoracic aortic wall than normal tricuspid valves did [28]. Besides, the increased wall shear stress has an uneven distribution in different aortic locations. With the structural changes of ascending aorta wall (such as atherosclerotic plaque), abnormal blood flow kinetic energy will be converted into static pressure, a continuous effect on the aorta [29]. Hemodynamic abnormalities weaken the structure of the aorta through the direct mechanical effect, leading to dissection or rupture, such abnormalities also affect the physiological activities of various cells in the aorta, including miRNAs’ expression [30].

Each pathogenic factor influences phenotypes of BAV-related TAA differently [31]. Those phenotypes can be divided basically into aortic root aneurysm and tubular aortic aneurysm. Aortic root dilation is strongly gene-driven, as to tubular phenotype, more hemodynamic inclined [32].

Since no single theory can fully explain its pathogenesis, BAV-related TAA may be a multifactorial disease. As the two important pathogenic factors mentioned previously, miRNA is involved in the post-transcriptional regulation of genes or act as hemodynamic-sensitive molecules.

The phenotypes of BAV malformation and BAV-related TAA

Heterogeneous as BAV is, classification of the valve malformation patterns and generalization of the thoracic aorta distension types are necessary.

Currently, BAV malformations are mainly detected by echocardiography and classified by Sievers classification, which is shown in Fig. 1 [33]. In a multicenter study involving patients, 1881 out of 2118 patients with BAV had fusion raphes (88.8%), and the remaining 11.2% were Type-0. The phenotype with the highest incidence was the fusion of the left and right coronary cusps (1435 patients, accounting for 76.3%), followed by the right-noncoronary cusps fusion (343 patients, accounting for 18.2%) [34].

Fig. 1
figure 1

Type 0 has no raphe (left), the direction of transverse or longitudinal openings is used as the basis for further classification. Type 1 has three subtypes (middle), of which L-R fusion has the highest incidence in patients with BAV malformation. Type 2 has bi-commissural fusions (right)

According to the location of dilated aortic segment, TAA is mainly divided into root dilation and tubular aorta dilation, and these two phenotypes account for 96% of patients with BAV-related TAA. The remaining 4% patients exhibit dilation in distal part of the ascending aorta, including proximal aortic arch. Tubular aorta dilation is of highest incidence, followed by root dilation, with less distal aorta dilation [35].

In a study by Della Corte A et al., two most prevalent patterns of BAV malformations are correlated with two different dilated segments of aorta: the fusion of the left and right coronary cusps at the root dilation, and the fusion of the right and noncoronary cusps at the tubular dilation. These relationships are morphological only, no correlations were seen between dilated segments and functional integrity of aortic valves [36]. Several studies have examined the relationship between the presence of raphes and the incidence of aortic stenosis and regurgitation in patients with BAV, indicating presence of raphes contributed to increased frequencies of valve dysfunction and greater valvular surgery demands.

Considering the diversity of BAV-related TAA phenotypes, once a study of BAV-related TAA did not differentiate these types, research bias could not be avoided from confounding factors. However, if the study population is not large enough for classification with strict criteria, reliability of the results needs to be discussed. Due to the specificity of root phenotypes, we suggest that root dilatation and tubular dilatation should be sorted broadly.

Role of miRNA in the pathogenesis of BAV

Disturbance of the extracellular matrix in the aorta

Extracellular matrix (ECM) is a tissue component mainly composed of collagen, elastin, proteoglycan and aminoglycan. It serves basically as supporting structure of cells, and participant in the cell phenotype regulations through signal transmission [37].

Recent studies on BAV-related TAA have focused on the degeneration of ECM caused by disturbance of matrix metalloproteinase (MMP) / tissue inhibitor of matrix metalloproteinases (TIMP) balance. In 2005, LeMaire SA et al. collected 29 samples of aneurysms (14 BAV-related TAA and 15 TAV-related TAA), and compared them with 14 healthy aorta samples. Differences were found in expression of MMP-2, MMP-9, TIMP-1 and TIMP-9 among the three groups [38]. In 2016, Jie Wu et al. divided BAV-related TAA into mild dilation group and severe dilation group. In aortic samples from the mild dilation group, they found that levels of miR-17 and miRNAs with same seed sequence as miR-17 increased significantly; while TIMP-1, TIMP-2 and TIMP-3 levels decreased and MMP-2 activity increased. In vitro experiments confirmed that miR-17 directly targeted TIMP-1 and TIMP-2 [39]. This study provided some evidences accounting for the continuous progression of BAV-related TAA.

In a bioinformatics study, a miRNAs cluster (located in the 14q32 locus on chromosome 14) centered on miR-494 was screened, and functional enrichment analysis of the cluster revealed that ECM was an important regulatory target of this cluster [40]. In addition, some studies have focused on the correlation between the expression of miRNAs with MMP/TIMP. In 2020, research of Shiho Naito et al. found that in BAV-related TAA aorta tissues, expression of miR-133a was positively correlated with TIMP-1 and 2, and expression of miR-143a was negatively correlated with MMP-2 [41]. Although the explorations of downstream cell signals and the potential targets of miRNA were not involved in these studies, the correlations also support the potential co-role of miRNA and MMP/TIMP in BAV-related TAA.

Regulation on the phenotype of aortic smooth muscle cells

Vascular smooth muscle cells (VSMCs) are mainly located in the middle thoracic aorta. Conversion from contractile phenotypes to secretory ones, abnormal proliferation and apoptosis of VSCMs can affect the vascular structure [42]. Some studies have focused on how miRNA contributed to BAV-related TAA progression by influencing VSMC phenotype. A study in 2016 by Sebastian Albinsson et al. showed differential expression characteristics of miRNAs found in different groups (BAV, TAV and heart transplant control groups) and different regions (convex and concave aortic regions). They further found that increase of miR-146-5p and miR-21-5p, which regulate the phenotype of SMC synthesis, and decrease of miR-133A-3p, which regulate the phenotype of SMC contraction, could be detected significantly in the convex region of BAV-related TAA [43]. In 2017, next-generation sequencing found that, compared with TAV-related TAA group, 12 miRNAs (2 up-regulated and 10 down-regulated) were differentially expressed in the BAV-related TAA group, among which miR-424-3p and miR-3688-3p were significantly down-regulated. These miRNAs were mainly involved in Hippo signaling pathway, ErbB signaling pathway and TGF-β signaling pathway. Coincidentally, these pathways are associated with cell proliferation and apoptosis. Although no evidences reported to support linkages between these signaling pathways and specific cell types (e.g., VSMC), these findings might lead to new ways for further researches [44].

Aortic dissection is one of the serious complications of BAV-related TAA, and miRNA also influences VSMC in dissection diseases, especially regulates apoptosis of VSMC. miRNA-related apoptosis in aortic dissection was initially identified in abdominal aortic aneurysms by Maegdefessel et al. [45], showing that miR-21 regulated VSMC apoptosis in murine models. In the cases of thoracic aorta dissection, researchers have found that miR-320d and miR-582 decrease in the thoracic aortic dissection tissues, and these two miRNAs were proved to be related to apoptosis by targeting the 3'UTR region of TRIAP1 and NET1 [46]. However, these studies on thoracic aortic dissection did not include BAV malformation, expression characteristics of miRNA and the relationship between miRNA and VSMC apoptosis may be different under BAV-related background.

Endothelial injury and endothelial phenotypic changes

Recent studies have shown that endothelial cells (ECs) are damaged by abnormal aortic blood flow, and phenotypic changes of ECs have been found in BAV-related TAA aortic tissues. These changes tend to participate in the weakening of the aortic structure of TAA, and may be inducers for aortic rupture or dissection. In a 2017 study, elevated PECAM + endothelial microparticles, shaping from the plasma membrane of ECs during activation, injury, or apoptosis, were found to be associated with aortic dilation in patients with BAV; moreover, a miR-494-centered miRNAs network was found associating with PECAM + endothelial microparticles [40]. According to study of Maleki et al. [47], the miR-200 family participates in the pathogenesis of BAV-related TAA through ECs. Compared with TAV group, expression of miR-200 family (miR-200c and miR-429) decreased in patients with BAV, while expression of their target genes increased. In vitro experiments also supported the involvement of miR-200 in the process of endothelial/epithelial mesenchymal transition (EndMT/EMT) [47].

These studies suggested the important role of miRNA-regulated ECs in the chronic structural weakness and acute structural destruction of BAV-related TAA.

Oxidative stress intolerance and calcification

In addition to ECM, VSMC phenotype and EC phenotype, intolerance to oxidative stress was also mentioned in some studies. In a study by Julie A et al. which focused on metallothionein (an antioxidant that is upregulated in response to oxidative stress), compared with the control group, 110 genes from patients with BAV-related TAA were changed, and 8 out of which were metallothionein-related. This indicated that BAV aorta was more sensitive to oxidative stress, BAV aortic dilation risk increased under oxidative stress [48]. Recently, abnormal regulation of miR-328-3p in the aortic valve of patients with BAV was reported to induce oxidative stress intolerance in valvular ECs [49]. Although no explicit associations of oxidative stress with miRNA-mediated BAV-related TAA were identified, these experiments provided part of evidences for pathogenesis of BAV-TAA through the regulation of oxidative stress by miRNA.

Calcification is one of the common pathological changes of aortic valves. miR-195 is down-regulated in patients with BAV and valve calcification was promoted through SMAD7 pathway [50]. miR-330-3p contributed to BAV aortic valve calcification by targeting CREBBP [51]. These studies also showed greater hemodynamics changes under the condition of valve calcification, proposed possibilities of structural weakness of aorta itself due to calcification.

Regulation of miRNAs

There are two ways of regulation on miRNA in the pathogenesis of BAV-related TAA, namely the transcription regulation and the epigenetic modification after transcription.

In the study by Alijbegovic et al., they speculated that actin polymerization promoted VSMC-specific gene expression through transcriptional coactivator MRTF in aneurysm, which may also include transcription regulation of miRNA [52]. As a study mentioned previously, miR-200 family regulates EndMT/EMT process, which suggested a high chromatin occupancy of miR-200c promoters by ZEB1/ZEB2, and a double-negative feedback loop of miR-200c and ZEB1/ZEB2 was more highly activated in patients with BAV [47].

Post-transcriptional modification of miRNA has not yet been studied in BAV-related TAA. However, in a study on cardiac hypertrophy in 2020, a modification of reactive oxygen species (ROS) at site 7 of the seed sequence of miR-1 was mentioned, and oxidized miR-1 played a special role in hypertrophic process of myocardium[17]. Post-transcriptional modification of miRNAs can also be involved in BAV-related TAA by analogy.

miRNAs as biomarkers for BAV-related TAA

Referring miRNAs as biomarkers, oncology studies will be covered in a lot. Stabilities of miRNAs in formalin-treated tissues [53] and circulating serum [54] enabled them effective biomarkers to predict the lesion progression of the aorta.

Studies on miRNAs as biomarkers of BAV-related TAA has been started long ago, drawing a series of conclusions through different phenotypic grouping methods and different correlation analyses. In 2013, expressions of miR-1 and miR-21 were found to be differed in serum of BAV-related and TAV-related TAA; and miR-133a was associated with the incidence of aneurysm [55]. Martinez-Micaelo et al. analyzed the expression level of miRNAs in the circulation of BAV-related aortic disease and found that miR-122, miR-130a and miR-486 were significantly affected by valve morphology. Moreover, miR-718 was negatively correlated with aortic diameter and could be used as an independent predictor of aortic dilatation, and it was enriched in vascular-remodeling-relating genes [56]. Girdauskas et al. [57] divided the dilated aorta into mild dilated and severe dilated aorta groups. In patients with BAV-related mild dilated aorta, miR-17 and miR-106a expressions were significantly higher than those of patients with severe dilated aorta, and significant reductions of miR-17 and miR-106a were observed in patients with BAV who experienced an adverse aortic event during subsequent follow-ups [57]. Another study in 2018 linking miRNA serum expression with NOTCH1 mutation revealed that miR-145 expression was significantly lower in a subgroup of patients with the NOTCH1 mutation than those without [58]. By A. Gallo et al., miR-15b was found to be an independent predictor of aortic dilatation, and the circulating level of miR-34a was negatively correlated with aortic wall elasticity in patients with BAV [59]. Lately a significant negative linear correlation was found between circulating miR-17, miR-20a, miR-106a and proximal aortic diameter [60].

As is shown in Fig. 2, miRNAs are used as circulating biomarkers mainly to identify BAV malformation (miR-1, miR-21, miR-122, miR-130a, miR-486), to confirm dilated diameter of the aorta (miR-718, miR-17, miR-106a, miR-15b, miR-20a), to check gene mutation (miR-145), and to clarify aortic wall characteristics (miR-34a). Imaging means up-to-date, such as echocardiography and computerized tomography (CT), is not accurate enough in determining BAV malformation and aneurysm diameter. miRNA biomarkers carrying more clinical significances could be conducive to illustrate the characteristics of aortic wall and the progression of BAV-related TAA.

Fig. 2
figure 2

In addition to directly involving in the pathogenesis of BAV-related TAA by affecting extracellular matrix (ECM), vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), miRNAs can also enter the circulatory system as biomarkers

Giving complex pathogenic backgrounds about BAV-related TAA, each single biomarker may not be reliable enough in specificity, sensitivity, and biological significance. Setting up a predictive model that includes a series of related biomarkers will be more credible for clinic applications.


Currently, much difficulties and confusions still lie in the treatment for BAV-related TAA. In this review, we show that miRNA has some perspective to address such problems.

Firstly, current studies have shown that miRNA affects ECM, VSMC and ECs by regulating the downstream pathways epigenetically, providing possible targets to intervene preoperatively and postoperatively to ameliorate aneurysm progression.

In the cell biology studies of BAV-related TAA, we believe that the research-target of miRNA itself and its downstream pathways are noteworthy in the following directions: (A) Post-transcriptional oxidative modification of miRNAs: As mentioned above, the characteristics of oxidative stress intolerance of BAV-related TAA provide objective conditions for oxidative modification. Oxidative modification of miRNA, especially in its seed sequence, will change its targeted binding site. Studies in this direction could help us to more accurately describe the expression characteristics and biological functions of miRNAs in BAV-related TAA. (B) Circular RNA: circular RNA can act as a sponge for miRNA, thus alleviating the inhibition of miRNA on target mRNA [61]. The studies of circular RNA can help us find a more complete regulatory axis of miRNA in the pathogenesis of BAV-related TAA.

Clinical application of miRNAs in BAV-related TAA: In addition to the intervention on miRNA-related downstream pathways and regulatory axis, the study of Yang H et al. in 2019 on miRNA delivery system constructed by nanoparticles for the treatment of myocardial infarction suggested that we could use protective-miRNA delivery system to delay the disease progression of BAV-related TAV [62]. In this part, the selection of protective-miRNA and the study of delivery systems are of great value.

Secondly, miRNAs are potential as biomarkers for this disease due to the tissue/circulating-stable characteristics, and can be used as a supplement for imaging means to determine surgery time and help decision-making in BAV-related TAA. Current studies have not found that a single miRNA has sufficient prediction accuracy for BAV-related TAA, and a prediction model involving multiple miRNAs is worthy of expectation. Moreover, most of the current studies on miRNAs as biomarkers only show statistical correlation, and the evidence of the association between these miRNAs and the pathological progression of BAV-related TAA also needs to be further studied. Although biomarker applications of these miRNAs need to be further validated in large scaled studies, such molecules are promising and we hope they will eventually be helpful in diagnosis and treatment of BAV-related TAA.

Availability of data and materials

Not applicable.



Bicuspid aortic valve


Thoracic aortic aneurysm


Vascular smooth muscle cells


Extracellular matrix


Endothelial cell


Matrix metalloproteinase


Tissue inhibitor of matrix metalloproteinases


  1. Ward C. Clinical significance of the bicuspid aortic valve. Heart. 2000;83(1):81–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Trimarchi S, et al. Contemporary results of surgery in acute type A aortic dissection: the International Registry of Acute Aortic Dissection experience. J Thorac Cardiovasc Surg. 2005;129(1):112–22.

    Article  PubMed  Google Scholar 

  3. Davies RR, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17–27 (discussion 27-8).

    Article  PubMed  Google Scholar 

  4. Pape LA, et al. Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation. 2007;116(10):1120–7.

    Article  PubMed  Google Scholar 

  5. Hiratzka LF, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Anesth Analg. 2010;111(2):279–315.

    Article  PubMed  Google Scholar 

  6. Andreassi MG, Della Corte A. Genetics of bicuspid aortic valve aortopathy. Curr Opin Cardiol. 2016;31(6):585–92.

    Article  PubMed  Google Scholar 

  7. Yap CH, et al. The congenital bicuspid aortic valve can experience high-frequency unsteady shear stresses on its leaflet surface. Am J Physiol Heart Circ Physiol. 2012;303(6):H721–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem. 2011;149(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  11. Sheu-Gruttadauria J, MacRae IJ. Structural foundations of RNA silencing by Argonaute. J Mol Biol. 2017;429(17):2619–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Liu J, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004;305(5689):1437–41.

    Article  CAS  PubMed  Google Scholar 

  13. Fukao A, et al. MicroRNAs trigger dissociation of eIF4AI and eIF4AII from target mRNAs in humans. Mol Cell. 2014;56(1):79–89.

    Article  CAS  PubMed  Google Scholar 

  14. Chen CY, et al. Ago-TNRC6 triggers microRNA-mediated decay by promoting two deadenylation steps. Nat Struct Mol Biol. 2009;16(11):1160–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Heo I, et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell. 2008;32(2):276–84.

    Article  CAS  PubMed  Google Scholar 

  16. Katoh T, et al. Selective stabilization of mammalian microRNAs by 3ʹ adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. Genes Dev. 2009;23(4):433–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Seok H, et al. Position-specific oxidation of miR-1 encodes cardiac hypertrophy. Nature. 2020;584(7820):279–85.

    Article  CAS  PubMed  Google Scholar 

  18. Gantier MP, et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 2011;39(13):5692–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xi Y, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Gurvitz M, et al. Frequency of aortic root dilation in children with a bicuspid aortic valve. Am J Cardiol. 2004;94(10):1337–40.

    Article  PubMed  Google Scholar 

  21. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol. 1997;30(7):1809–12.

    Article  CAS  PubMed  Google Scholar 

  22. Brown C, Sane DC, Kitzman DW. Bicuspid aortic valves in monozygotic twins. Echocardiography. 2003;20(2):183–4.

    Article  PubMed  Google Scholar 

  23. Garg V, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437(7056):270–4.

    Article  CAS  PubMed  Google Scholar 

  24. Mohamed SA, et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun. 2006;345(4):1460–5.

    Article  CAS  PubMed  Google Scholar 

  25. Gould RA, et al. ROBO4 variants predispose individuals to bicuspid aortic valve and thoracic aortic aneurysm. Nat Genet. 2019;51(1):42–50.

    Article  CAS  PubMed  Google Scholar 

  26. Bjornsson T, et al. A rare missense mutation in MYH6 associates with non-syndromic coarctation of the aorta. Eur Heart J. 2018;39(34):3243–9.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Patel V, et al. The stretch responsive microRNA miR-148a-3p is a novel repressor of IKBKB, NF-kappaB signaling, and inflammatory gene expression in human aortic valve cells. Faseb j. 2015;29(5):1859–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Viscardi F, et al. Comparative finite element model analysis of ascending aortic flow in bicuspid and tricuspid aortic valve. Artif Organs. 2010;34(12):1114–20.

    Article  PubMed  Google Scholar 

  29. Juraszek A, et al. The influence of bicuspid aortic valves on the dynamic pressure distribution in the ascending aorta: a porcine ex vivo model. Eur J Cardiothorac Surg. 2014;46(3):349–55 (discussion 355).

    Article  PubMed  Google Scholar 

  30. Yildirim E, et al. Circulating miR-21 levels in hypertensive patients with asymptomatic organ damage. Medicine (Baltimore). 2019;98(39):e17297.

    Article  CAS  Google Scholar 

  31. Della Corte A. Phenotypic heterogeneity of bicuspid aortopathy: a potential key to decode the prognosis? Heart. 2014;100(2):96–7.

    Article  PubMed  Google Scholar 

  32. Yassine NM, Shahram JT, Body SC. Pathogenic mechanisms of bicuspid aortic valve aortopathy. Front Physiol. 2017;8:687.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sievers HH, Schmidtke C. A classification system for the bicuspid aortic valve from 304 surgical specimens. J Thorac Cardiovasc Surg. 2007;133(5):1226–33.

    Article  PubMed  Google Scholar 

  34. Kong WK, et al. Prognostic implications of raphe in bicuspid aortic valve anatomy. JAMA Cardiol. 2017;2(3):285–92.

    Article  PubMed  Google Scholar 

  35. Girdauskas E, et al. Functional aortic root parameters and expression of aortopathy in bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2016;67(15):1786–96.

    Article  PubMed  Google Scholar 

  36. Della Corte A, et al. Towards an individualized approach to bicuspid aortopathy: different valve types have unique determinants of aortic dilatation. Eur J Cardiothorac Surg. 2014;45(4):e118–24 (discussion e124).

    Article  PubMed  Google Scholar 

  37. Miranti CK, Brugge JS. Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 2002;4(4):E83-90.

    Article  CAS  PubMed  Google Scholar 

  38. LeMaire SA, et al. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res. 2005;123(1):40–8.

    Article  CAS  PubMed  Google Scholar 

  39. Wu J, et al. Progressive aortic dilation is regulated by miR-17-associated miRNAs. J Am Coll Cardiol. 2016;67(25):2965–77.

    Article  CAS  PubMed  Google Scholar 

  40. Martínez-Micaelo N, et al. MicroRNAs clustered within the 14q32 locus are associated with endothelial damage and microparticle secretion in bicuspid aortic valve disease. Front Physiol. 2017;8:648.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Naito S, et al. Bicuspid aortopathy—molecular involvement of microRNAs and MMP-TIMP. Biomarkers. 2020;25(8):711–8.

    Article  CAS  PubMed  Google Scholar 

  42. Malashicheva A, et al. Phenotypic and functional changes of endothelial and smooth muscle cells in thoracic aortic aneurysms. Int J Vasc Med. 2016;2016:3107879.

    PubMed  PubMed Central  Google Scholar 

  43. Albinsson S, et al. Patients with bicuspid and tricuspid aortic valve exhibit distinct regional microrna signatures in mildly dilated ascending aorta. Heart Vessels. 2017;32(6):750–67.

    Article  PubMed  Google Scholar 

  44. Borghini A, et al. miRNome profiling in bicuspid aortic valve-associated aortopathy by next-generation sequencing. Int J Mol Sci. 2017;18(11):2498.

    Article  PubMed Central  CAS  Google Scholar 

  45. Maegdefessel L, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4(122):122ra22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Shen H, et al. hsa-miR-320d and hsa-miR-582, miRNA biomarkers of aortic dissection, regulate apoptosis of vascular smooth muscle cells. J Cardiovasc Pharmacol. 2018;71(5):275–82.

    Article  CAS  PubMed  Google Scholar 

  47. Maleki S, et al. The mir-200 family regulates key pathogenic events in ascending aortas of individuals with bicuspid aortic valves. J Intern Med. 2019;285(1):102–14.

    Article  CAS  PubMed  Google Scholar 

  48. Phillippi JA, et al. Basal and oxidative stress-induced expression of metallothionein is decreased in ascending aortic aneurysms of bicuspid aortic valve patients. Circulation. 2009;119(18):2498–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Poggio P, et al. MiRNA profiling revealed enhanced susceptibility to oxidative stress of endothelial cells from bicuspid aortic valve. J Mol Cell Cardiol. 2019;131:146–54.

    Article  CAS  PubMed  Google Scholar 

  50. Du J, et al. Downregulated MicroRNA-195 in the bicuspid aortic valve promotes calcification of valve interstitial cells via targeting SMAD7. Cell Physiol Biochem. 2017;44(3):884–96.

    Article  CAS  PubMed  Google Scholar 

  51. Zheng R, et al. Upregulated microRNA-330-3p promotes calcification in the bicuspid aortic valve via targeting CREBBP. Mol Med Rep. 2020;22(3):2351–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Alajbegovic A, Holmberg J, Albinsson S. Molecular regulation of arterial aneurysms: role of actin dynamics and microRNAs in vascular smooth muscle. Front Physiol. 2017;8:569.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Li J, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ikonomidis JS, et al. Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013;145(5):1326–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Martínez-Micaelo N, et al. Specific circulating microRNA signature of bicuspid aortic valve disease. J Transl Med. 2017;15(1):76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Girdauskas E, et al. Evaluation of microribonucleic acids as potential biomarkers in the bicuspid aortic valve-associated aortopathy. Interact Cardiovasc Thorac Surg. 2018;27(1):60–6.

    Article  PubMed  Google Scholar 

  58. Girdauskas E, et al. MiR-145 expression and rare NOTCH1 variants in bicuspid aortic valve-associated aortopathy. PLoS ONE. 2018;13(7):e0200205.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Gallo A, et al. On the prospect of serum exosomal miRNA profiling and protein biomarkers for the diagnosis of ascending aortic dilatation in patients with bicuspid and tricuspid aortic valve. Int J Cardiol. 2018;273:230–6.

    Article  PubMed  Google Scholar 

  60. Girdauskas E, et al. Expression patterns of circulating MicroRNAs in the risk stratification of bicuspid aortopathy. J Clin Med. 2020;9(1):276.

    Article  CAS  PubMed Central  Google Scholar 

  61. Militello G, et al. Screening and validation of lncRNAs and circRNAs as miRNA sponges. Brief Bioinform. 2017;18(5):780–8.

    CAS  PubMed  Google Scholar 

  62. Yang H, et al. An in vivo miRNA delivery system for restoring infarcted myocardium. ACS Nano. 2019;13(9):9880–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable


This work is supported by the National Natural Science Foundation of China (Grant No. 81671942), Yongxin Sun; the National Natural Science Foundation of China (Grant No. 81700256), Le Kang.

Author information

Authors and Affiliations



HJ analyzed and interpreted the research progress of miRNA in bicuspid aortic aneurysm, and was a major contributor in writing the manuscript. LK was the funding provider for this study and participated in the analysis of research progress. ZM participated in the writing of the first draft and the revision of the manuscript. SL and BH were involved in the analysis and interpretation of the frontier progress of miRNA in bicuspid aortic aneurysm. CW was a contributor of the conceptual design of this research. YZ was a contributor of the conceptual design and the revision of this manuscript. YS was a major contributor of the conceptual design, the revision, and the funding of this manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Chunsheng Wang, Yunzeng Zou or Yongxin Sun.

Ethics declarations

Ethics approval and consent to participate

This review did not report on or involve the use of any animal or human data or tissue and received an ethical exemption document from the Ethics Committee of Zhongshan Hospital, Fudan University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, H., Kang, L., Ma, Z. et al. MicroRNAs involve in bicuspid aortic aneurysm: pathogenesis and biomarkers. J Cardiothorac Surg 16, 230 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: